01—Abstract
Summary
Summary of the 10-K filed February 14, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (CRL) reported fiscal 2023 total revenue of $4.13 billiona, up from $3.98 billion in 2022, an increase of $153.3 million or 3.9%, driven mainly by Safety Assessment volume and pricing and the Explora BioLabs acquisition, partially offset by the Avian divestiture.
Operating income declined to $617.3 millionb (14.9% margin) from $651.0 million (16.4%), reflecting higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders was $474.6 million, versus $486.2 million in 2022, while cash flow from operations rose to $683.9 million from $619.6 million. Segment revenue was RMS $792.3 million, DSA $2.62 billion (63.3% of total revenue), and Manufacturing $721.4 million.
The filing highlights several risks. Non-human primate supply is constrained after the company voluntarily suspended shipments of Cambodia-sourced primates into the U.S. amid a DOJ and USFWS grand jury and civil investigation, an SEC inquiry, a putative securities class action and a derivative lawsuit. The company says it cannot predict the timing or outcome of these matters, including potential fines or liabilities.
Total debt and finance leases were $2.6 billionc, and the company completed the Noveprim acquisition, which lifted its stake to 90%. Discovery Services demand declined and DSA backlog fell to $2.45 billion from $3.15 billion. Restructuring charges were about $30 million, with expected annualized savings of $60 million to $70 million.
The company had $129.1 milliond remaining under its $1.3 billion stock repurchase authorization and did not repurchase shares in the fourth quarter. It paid no cash dividends in 2023 and does not plan to in the coming year.
02—Key points
Key Highlights
- Revenue of $4.13 billion, up 3.9% year over year, led by DSA Safety Assessment volume and pricing.
- Operating income fell to $617.3 million (14.9% margin) from $651.0 million (16.4%), driven by Manufacturing costs, restructuring and impairments, and the Avian divestiture.
- Net income attributable to common shareholders was $474.6 million, compared with $486.2 million in 2022; diluted EPS was $9.22 versus $9.48.
- Non-human primate supply is constrained: Cambodia-sourced shipments are voluntarily suspended amid DOJ, USFWS and SEC investigations and securities and derivative lawsuits.
- DSA backlog declined to $2.45 billion from $3.15 billion, and Discovery Services demand weakened in 2023.
- Total debt and finance leases were $2.6 billion; operating cash flow rose to $683.9 million from $619.6 million.
- No share repurchases in Q4 2023; $129.1 million remains under the $1.3 billion authorization, and no cash dividends were paid.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 14, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $4.13B$3.98B | +3.9% |
| SG&A Expenses | $747.86M$665.10M | +12.4% |
| Operating Income | $617.26M$650.98M | −5.2% |
| Interest Expense | $136.71M$59.29M | +130.6% |
| Net Income | $474.62M$486.23M | −2.4% |
| EPS (Basic) | $9.27$9.57 | −3.1% |
| EPS (Diluted) | $9.22$9.48 | −2.7% |
| Shares Outstanding (Basic) | 51.23M50.81M | +0.8% |
| Shares Outstanding (Diluted) | 51.45M51.30M | +0.3% |
05—Questions
Frequently Asked Questions
How did Charles River's revenue and profitability trend in fiscal 2023?
Total revenue rose to $4.13 billion from $3.98 billion, an increase of $153.3 million or 3.9%. Operating income fell to $617.3 million from $651.0 million, and operating margin declined to 14.9% from 16.4%, mainly due to higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders decreased to $474.6 million from $486.2 million.
What is the main legal and regulatory risk facing the company?
The company is cooperating with DOJ and USFWS investigations, including a grand jury investigation, into shipments of non-human primates from Cambodia, and with an SEC inquiry. It also faces a putative securities class action and a derivative lawsuit. The company states it cannot predict the timing, outcome or possible impact of these matters, including any fines, penalties or liabilities, and has voluntarily suspended future Cambodia-sourced primate shipments to the U.S.
How is the company's segment performance differing?
DSA, the largest segment at $2.62 billion in revenue (63.3% of total), grew 6.9% and raised operating income to $606.1 million. RMS revenue rose to $792.3 million, but its operating income fell to $154.7 million. Manufacturing revenue declined to $721.4 million, and its operating income dropped to $88.3 million from $167.1 million, largely due to the Avian divestiture and higher costs.
What capital allocation activity did the company undertake in 2023?
The company completed the Noveprim acquisition, raising its stake to a 90% controlling interest, and acquired SAMDI Tech. Net cash used in investing activities was $563.2 million, including capital expenditures of $318.5 million. The company did not repurchase shares under its $1.3 billion program in the fourth quarter, with $129.1 million remaining, and paid no cash dividends.
06—Continue